Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hereditary haemochromatosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Hereditary haemochromatosis. Displaying page 1 of 1.
    EudraCT Number: 2006-002099-16 Sponsor Protocol Number: 06/Q0703/56 Start Date*: 2006-07-13
    Sponsor Name:King's College London
    Full Title: The effect of milk thistle extract (Legalon) versus tea on serum iron increase after a meal containing non-haem iron in hereditary haemochromatosis
    Medical condition: Type 1 hereditary haemochromatosis is associated with homozygous inheritance of the C282Y mutation in the HFE gene. The phenotype is characterised by increased serum iron levels, tissue iron accumu...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057873 Hereditary haemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002102-57 Sponsor Protocol Number: CICL670A2202 Start Date*: 2006-10-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
    Medical condition: hereditary hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000360-16 Sponsor Protocol Number: P030 Start Date*: 2009-08-06
    Sponsor Name:Medizinische Universität Innsbruck, Innere Medizin I
    Full Title: EFFECTS OF NIFEDIPINE ON IRON HOMEOSTASIS IN PATIENTS SUFFERING FROM IRONOVERLOAD DISEASES - Effekte von Nifedipin auf die Eisenhomeostase bei Patienten mit Eisenüberladungsstörungen
    Medical condition: Hämochromatose ist eine Gruppe genetischer Erkrankungen (Mutationen) denen eine erhöhte Transferrinsättigung und Ferritinspiegel im Blut und Eisenablagerung in Organen, vor allem Leber, Bauchspeich...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057874 Hereditary hemochromatosis LLT
    9.1 10057876 Secondary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002529-12 Sponsor Protocol Number: CICL670F2203 Start Date*: 2017-10-19
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012236 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003777-34 Sponsor Protocol Number: NL63198.041.17 Start Date*: 2018-02-09
    Sponsor Name:UMC Utrecht
    Full Title: Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.
    Medical condition: Iron overload (secondary hemochromatosis) in non-transfusion dependent forms of hereditary anemias. Iron overload and hereditary anemia are a growing, underestimated emerging health care problem.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    20.0 100000004861 10057875 Secondary haemochromatosis LLT
    20.0 100000004861 10022979 Iron excess HLT
    20.0 100000004850 10055610 Hemoglobinopathy LLT
    20.0 100000004850 10074356 Non-transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:53:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA